9,10-seco- Cyclopentanohydrophenanthrene Ring System (e.g., Vitamin D, Etc.) Doai Patents (Class 514/167)
  • Patent number: 10278918
    Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: May 7, 2019
    Assignee: Ocuphire Pharma, Inc.
    Inventor: Alan Meyer
  • Patent number: 10245250
    Abstract: Methods for improving the visual processing of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are disclosed. Methods for improving the visual acuity of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed. Methods for improving the development of the visual processing, visual acuity, or both, of an infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: April 2, 2019
    Assignee: ABBOTT LABORATORIES
    Inventors: Matthew Kuchan, Chron-Si Lai, Jacqueline Boff
  • Patent number: 10226511
    Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: March 12, 2019
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 10213439
    Abstract: The present invention is a compound comprising an anti-inflammatory drug component consisting preferably of at least one of an NSAID portion and a cannabis portion and at least one of a progestin component and a progesterone component. The compound may take for instance the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, or a suppository. The compound is intended for use in treating subjects having or being at increased risk—especially genetically determined risk—of developing endometriosis. The compound may also be used for treating other disorders or as a contraceptive.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: February 26, 2019
    Assignee: Predictive Therapeutics, LLC
    Inventor: Bradley C. Robinson
  • Patent number: 10188603
    Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of sexual dysfunction. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: January 29, 2019
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 10149831
    Abstract: The present invention relates to a pharmaceutical; composition comprising an effective amount of vitamin C, zinc, vitamin A, vitamin D3, vitamin B6, garlic and Echinacea to treat bacterial and/or viral infections, and a method for treating bacterial and/or viral infections by orally administering the composition to a patient effective to reduce symptoms of bacterial and/or viral infections such a cold and influenza.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: December 11, 2018
    Inventor: Edward Wick
  • Patent number: 10122590
    Abstract: A network tracing engine is configured to trace and depict a topology (i.e., a network configuration) of a network using, for example, a network diagram. The network tracing engine preferably queries/telnets to interfaces of routers associated with one or more source-to-destination paths in a network concurrently and independently to ensure proper configuration of the routers and/or to generate a true depiction of a routing configuration without redundantly querying routers.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: November 6, 2018
    Assignee: AT&T INTELLECTUAL PROPERTY I, L.P.
    Inventor: Raymond Washburn
  • Patent number: 10111896
    Abstract: The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 30, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.S.), Universite Paris Descartes, Foundation Imagine, Universite Paris Diderot—Paris 7, Universite Paris—Sud, Assistance Publique-Hopitaux de Paris (APHP)
    Inventors: Ivan Cruz-Moura, Olivier Hermine, Etienne Paubelle, Michael Dussiot, Thiago Trovati Maciel, Florence Zylbersztejn
  • Patent number: 10098897
    Abstract: This document provides methods and materials for reducing development of stenosis of arteriovenous fistulas. For example, methods and materials for reducing IEX-1 polypeptide expression or activity within a mammal (e.g., a human) to reduce venous neointimal hyperplasia and/or the development of stenosis of arteriovenous fistulas are provided.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: October 16, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Sanjay Misra, Rajiv Kumar
  • Patent number: 10071958
    Abstract: According to the present invention, it becomes possible to perform a process for converting into an ?-substituted cysteine represented by general formula (1) or a salt thereof at low cost and on an industrial scale by employing a process that is routed through a compound represented by general formula (3) to a compound represented by general formula (6). Particularly, by employing a process that is routed through a compound represented by general formula (7-2), it becomes possible to detach a tert-butyl protection group in a simple manner and to produce the compound represented by general formula (1) with high purity. Furthermore, by employing a process that is routed through tert-butylthiomethanol or a process that is routed through a compound represented by general formula (9), it becomes possible to produce a compound represented by general formula (2) without generating bischloromethylether that is an oncogenic substance.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: September 11, 2018
    Assignee: API Corporation
    Inventors: Yuuki Asuma, Hisatoshi Uehara, Tomoko Maeda, Yasuyo Saito, Ryoma Miyake, Hiroshi Kawabata
  • Patent number: 10046000
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 14, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Julia B. Zella, Margaret Clagett-Dame
  • Patent number: 10034898
    Abstract: The present invention generally relates to compositions and methods for treatment of various inflammatory diseases, such as inflammatory dermatoses and other conditions, e.g., using nitric oxide. Examples of such dermatoses include psoriasis, atopic dermatitis, and contact dermatitis. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto an inflammation site, or other suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: July 31, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 10034896
    Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of osteoporosis or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto a suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: July 31, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 10034897
    Abstract: The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth or repair. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth is desired, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: July 31, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9993457
    Abstract: Methods for improving the visual processing of a healthy infant by administering a composition comprising RRR-alpha-tocopherol and a carotenoid to the infant are disclosed. Methods for improving the visual acuity of a healthy infant by administering a composition comprising RRR-alpha-tocopherol and a carotenoid to the infant are also disclosed. Methods for improving the visual processing of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are disclosed. Methods for improving the visual acuity of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed. Methods for improving the development of the visual processing, visual acuity, or both, of an infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: June 12, 2018
    Assignee: Abbott Laboratories
    Inventors: Matthew Kuchan, Chron-Si Lai, Jacqueline Boff
  • Patent number: 9968634
    Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of neuropathic pain or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with neuropathic pain, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: May 15, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9968635
    Abstract: The present invention generally relates to compositions and methods for treatment of skin and/or other soft tissues that are infected with bacteria such as Staphylococcus aureus, and/or other infectious organisms. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a site of infection, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: May 15, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9950004
    Abstract: The present invention generally relates to compositions and methods for transdermal drug delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: April 24, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9943530
    Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: April 17, 2018
    Assignee: OPKO RENAL, LLC
    Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
  • Patent number: 9937162
    Abstract: Methods are provided of treating and preventing stroke diseases, such as cerebral cavernous malformation, by the administration of tempol and/or cholecalciferol.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: April 10, 2018
    Assignee: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Christopher C. Gibson, Dean Y. Li
  • Patent number: 9913852
    Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: March 13, 2018
    Assignees: OPKO IRELAND GLOBAL HODLINGS, LTD., OPKO RENAL, LLC
    Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig
  • Patent number: 9901576
    Abstract: Stable phenobarbital sodium solutions for injection that do not generate impurities during extended storage. These solutions include phenobarbital sodium in an amount of 15 to 200 mg/mL; a C1-C4 alcohol such as ethanol in an amount of 105 to 160 mg/mL; and a glycol such as propylene glycol in an amount of between 620 and 830 mg/mL and have a pH of between 9 and 12 which is adjusted to that range by adding acid or base, as required. No more than 50 mg/mL water is present including any water introduced by the acid or base. The solutions contain no more than 0.8% of phenyl ethyl acetyl urea impurity as well as no detectable amount of phenyl butyric acid after two years storage at room temperature.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: February 27, 2018
    Assignee: West-Ward Pharmaceuticals International Limited
    Inventors: Michael G. Parker, Scott S. Wilson, Yasmeen Chahal, Kelly W. Hovius, David E. McAnany
  • Patent number: 9877975
    Abstract: The present invention aims to provide an agent for treating meibomian gland dysfunction. The present invention provides an agent for treating meibomian gland dysfunction, which contains activated vitamin D3 or a derivative thereof as an active ingredient.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 30, 2018
    Assignee: Keio University
    Inventors: Kazuo Tsubota, Reiko Arita, Masataka Ito
  • Patent number: 9861644
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 9, 2018
    Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
  • Patent number: 9844565
    Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of acne or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with acne, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: December 19, 2017
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9814736
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: November 14, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
  • Patent number: 9775903
    Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: October 3, 2017
    Assignees: JOHNS HOPKINS UNIVERSITY, OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
  • Patent number: 9757392
    Abstract: The present invention discloses a novel use of a lanostane having the following formula (I) in enhancing uptake of nutrients: wherein R1 is either H or CH3; R2 is OCOCH3, ?O or OH; R3 is H or OH; R4 is —C(?CH2)—C(CH3)2Ra, in which Ra is H or OH, or —CH?C(CH3)—Rb, in which Rb is CH3 or CH2OH; R5 is H or OH; and R6 is CH3 or CH2OH.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: September 12, 2017
    Assignee: Sinphar Pharmaceutical Co., Ltd.
    Inventors: Hang-Ching Lin, Tsu-Chung Chang, Wen-Liang Chang, Yi-Yang Song
  • Patent number: 9717704
    Abstract: The present invention relates to the treatment and/or prevention of Alzheimer's Disease or the symptoms associated therewith by daily administration of a drink formula comprising fresh marine omega-3 oil in an emulsion and resveratrol or derivatives thereof.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: August 1, 2017
    Assignee: Smartfish AS
    Inventors: Janne Sande Mathisen, Henrik Mathisen
  • Patent number: 9722880
    Abstract: The preferred embodiments of the present invention are directed to a network tracing engine for tracing and depicting a topology (i.e. a network configuration) of a network using, for example, a network diagram. The network tracing engine preferably queries/telnets to interfaces of routers associated with one or more source-to-destination paths in a network concurrently and independently to ensure proper configuration of the routers and/or to generate a true depiction of a routing configuration without redundantly querying routers.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: August 1, 2017
    Assignee: AT&T INTELLECTUAL PROPERTY I, L.P.
    Inventor: Raymond Washburn
  • Patent number: 9707243
    Abstract: The topical composition with Vitamin D3 includes Vitamin D3, one or more aromatic oils, and aloe vera gel. Vitamin D3 is soluble in aromatic oils, and aloe vera gel enables transport through the stratum corneum so that the composition may be used for fulfilling daily requirements, treatment of bone conditions, such as rickets and osteomalacia, and supportive therapy in osteopenia and osteoporosis. The aromatic oil may be a citric acid extract (e.g., orange oil extracted from orange peels), lavender oil, or any other aromatic oil in which Vitamin D3 is soluble. Optionally, the composition may include excipients, such as a permeability enhancer (e.g., glycerine and water), a preservative (e.g., a carbomer, methyl paraben, EDTA, or the like), or other additives that do not affect the active ingredients. The composition is preferably formulated as a cream or emulsion.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: July 18, 2017
    Inventors: Sadat A. Ali, Haifa Abdulaziz Alturki
  • Patent number: 9687441
    Abstract: Compositions for lubricating skin during application of a fascia tissue treatment device, thereby reducing the appearance of cellulite in skin and methods of forming such compositions.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: June 27, 2017
    Assignee: Ashley Diana Black International Holdings, LLC
    Inventor: Ashley D. Black
  • Patent number: 9671414
    Abstract: Described herein are assays directed to determining the level of bioavailable or free vitamin D in a blood sample in a subject. The values determined for bioavailable or free vitamin D indicate whether the subject suffers from insufficient levels of vitamin D. Also described herein are methods of treatment for vitamin D insufficiency.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: June 6, 2017
    Assignees: Beth Israel Deaconess Medical Center, Inc., The General Hospital Corporation
    Inventors: Ravi Thadhani, S. Ananth Karumanchi, Anders Hayden Berg, Ishir Bhan
  • Patent number: 9663429
    Abstract: The present invention relates to compounds of pharmaceutical interest. More particularly, it relates to compounds of formula (I), to processes for obtaining thereof, to the intermediates of their synthesis and processes for obtaining the latter. The compounds of formula (I) have a certain affinity with the vitamin D receptor, they are active in a similar order to 1,25?-dihydroxyvitamin D3 (1,25D), with the advantage of producing less or no hypercalcemia.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: May 30, 2017
    Assignees: UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, UNIVERSIDADE DA CORUNA, SERVIZO GALEGO DE SAUDE (SERGAS)
    Inventors: Roman Perez Fernandez, Samuel Seoane Ruzo, Antonio Mouriño Mosquera, Miguel Maestro Saavedra, Jose Esteban Castelao Fernandez, Pranjal Gogoi
  • Patent number: 9606131
    Abstract: Described herein are assays directed to determining the level of bioavailable or free vitamin D in a blood sample in a subject. The values determined for bioavailable or free vitamin D indicate whether the subject suffers from insufficient levels of vitamin D. Also described herein are methods of treatment for vitamin D insufficiency.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: March 28, 2017
    Assignees: The General Hospital Corporation, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Ravi Thadhani, S. Ananth Karumanchi, Anders Hayden Berg, Ishir Bhan
  • Patent number: 9539264
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: January 10, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
  • Patent number: 9539231
    Abstract: A targeted approach toward the treatment of TN breast cancer by using AMPI-109 is disclosed. AMPI-109 is a compound with remarkable “cancer-specific” characteristics. In particular, AMPI-109 demonstrates a striking targeted capability to inhibit the proliferation of TN breast cancer cells and to induce apoptosis in TN breast cancer cells. The growth inhibitory effect of AMPI-109 is independent of VDR. AMPI-109 can also be coupled with other oncolytic agents in treating a patient with TN breast cancer.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: January 10, 2017
    Assignees: The Regents of the University of Colorado, a body corporate, Trustees of Boston University
    Inventors: Hamid Gari, Jim Lambert, Scott Lucia, Rahul Ray, Ann Thor
  • Patent number: 9517241
    Abstract: Methods of treating patients with inflammatory bowel disease, intestinal fibrosis, or Crohn's disease involve administering a therapeutic amount of CARD-024 or related compound.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: December 13, 2016
    Assignee: The Regents Of The University Of Michigan
    Inventors: Robert U. Simpson, Peter D. R. Higgins, Laura A. Johnson
  • Patent number: 9492493
    Abstract: A softgel of NLKJ for the treatment of prostate diseases, comprising 0.05-1.0 g of NLKJ and 0.05-1.5 mg of an antioxidant, said NLKJ having the following physicochemical parameter: acid value<0.56, iodine value 95.0-107.00, saponification value 185.00-195.00, specific gravity 0.914-0.918 (20° C.), and refractive index 1.470-1.475 (20° C.). The inhibition of the softgel of NLKJ on the growth of prostate cancer in combination with the injection of Lupron is stronger than that of each of them used alone.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: November 15, 2016
    Inventor: Dapeng Li
  • Patent number: 9492552
    Abstract: The invention relates to injectable pharmaceutical compositions, methods of use and formulation, wherein the compositions comprise: one or more water soluble complexes, each complex comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug; at least one preservative; and at least one co-solvent. The compositions are effectively preserved in accordance with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the B criteria as it applies to parenterals, and the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing, satisfying the criteria for Category 1 (injectable) products.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: November 15, 2016
    Assignee: JUROX PTY LTD
    Inventors: Kirby Shawn Pasloske, Kai Lau, Sarah Jane Richardson, Amanda Aileen Willis
  • Patent number: 9465039
    Abstract: The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: October 11, 2016
    Assignee: MYCARTIS NV
    Inventors: Koen Kas, Griet Vanpoucke, Piet Moerman
  • Patent number: 9402855
    Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: August 2, 2016
    Assignees: OPKO RENAL, LLC, OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig
  • Patent number: 9387201
    Abstract: This disclosure provides products, including pharmaceutical compositions and dietary supplements, which are useful for anti-inflammatory support.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: July 12, 2016
    Assignee: RCP Development, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 9381183
    Abstract: This invention relates to methods for improving changing the quality of the meibum composition of the meibomian glands to enhance or improve the lipid layer of the tear and increase tear breakup time by way of elevating the omega-3 index in patients suffering from symptoms of dry eye, posterior blepharitis, and/or meibomian gland dysfunction. The methods comprise administering a supplementation of omega-3 fatty acids to a patient having an inflamed meibomian gland so as to facilitate an increase in the amount of omega-3's acting as an anti-inflammatory and, respectively, decrease the amount of omega-6's (arachidonic acid) acting as an inflammatory in the composition of the meibum, thereby normalizing the lipid layer of the tear and effectively reducing the associated symptoms. In certain embodiments, the supplementation of omega-3's comprises the esterified or re-esterified triglyceride form.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: July 5, 2016
    Assignee: Physicians Recommended Nutriceuticals, LLC
    Inventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
  • Patent number: 9370527
    Abstract: Methods of treating patients with inflammatory bowel disease, intestinal fibrosis, or Crohn's disease involve administering a therapeutic amount of CARD-024 or related compound.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: June 21, 2016
    Assignee: The Regents Of The University Of Michigan
    Inventors: Robert U. Simpson, Peter D. R. Higgins, Laura A. Johnson
  • Patent number: 9359277
    Abstract: The present invention relates to compositions, for example, the DBU/Hexafluoroacetone hydrate salt, and processes of preparing and using the same for the modification of chemical compounds via the release of trifluoroacetate. The DBU/Hexafluoroacetone hydrate salt can perform trifluoromethylation reactions on chemical compounds, such as carbonyl group-containing compounds.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: June 7, 2016
    Assignee: Purdue Research Foundation
    Inventors: David A. Colby, Mark V. Riofski, Changho Han
  • Patent number: 9320764
    Abstract: A method for enhancing production of Vitamin D within a person's skin includes a source of Vitamin D, a sunlight exposure indicator, and a sunscreen. Vitamin D, for example, cod liver oil, is applied to the skin topically via a patch or towlette, or ingested orally. The exposure indicator is worn by the user and changes its state to indicate that the person has been exposed to sunlight for a predetermined period of time. The user preferably waits a sufficient time for the Vitamin D to be absorbed into the skin, and then exposes his or her skin to direct sunlight, and monitors the exposure indicator to determine if it has changed state. The user applies the sunscreen to the user's skin after the exposure indicator changes state.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: April 26, 2016
    Assignee: TOPICAL TECHNOLOGIES, INC.
    Inventor: David S. Alberts
  • Patent number: 9241919
    Abstract: Embodiments of the invention relate to methods and compositions for treating symptoms related to inflammatory conditions and to methods and compositions for treating inflammatory components of common cold, utilizing various method of administration of X-ray contrast media (CM).
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: January 26, 2016
    Assignee: 3E THERAPEUTICS CORPORATION
    Inventors: Elliott C. Lasser, Kenneth H. Lasser
  • Patent number: 9241904
    Abstract: The present invention is related to metered dose inhalation formulas and manufacturing process. The active pharmaceutical ingredient can be beta-2 agonists, corticosteroids, or a combination thereof. The inhalation formulas are homogenized suspensions with hydrofluoroalkane (HFA) propellant, minimal amount of ethanol and polyetheleneglycol (PEG) as suspending and particle size modifying agents.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: January 26, 2016
    Assignee: INTECH BIOPHARM LTD.
    Inventors: Wei-Hsiu Wu, Yen-Chin Chao
  • Patent number: 9212137
    Abstract: Disclosed are methods of purifying the compound (20R,22R)-2-methylene-19-nor-22-methyl-1?,25-dihydroxyvitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving a product containing the compound in a solvent comprising hexane and 2-propanol, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of crystals, and recovering the crystals. Certain diol precursors formed during the synthesis of the compound and its diasteromers also may be obtained in crystalline form using ethyl acetate as a solvent.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 15, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Pawel Grzywacz, Lori A. Plum, Agnieszka Flores, James B. Thoden, Hazel M. Holden